# **PRODUCT** INFORMATION



**Ornidazole-d**<sub>5</sub>

Item No. 33810

CAS Registry No.:	
Formal Name:	α-(chloro(methyl-d <sub>2</sub> ))-2-methyl-5-nitro-1H-
	imidazole-1-ethan-α,β,β-d <sub>3</sub> -ol
Synonym:	(±)-Ornidazole-d <sub>5</sub> O <sub>2</sub> N D D D D
MF:	$C_7H_5D_5CIN_3O_3$
FW:	224.7 CI
<b>Chemical Purity:</b>	≥98% (Ornidazole)
Deuterium	N OH
Incorporation:	≥99% deuterated forms (d <sub>1</sub> -d <sub>5</sub> ); ≤1% d <sub>0</sub>
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.	

# Laboratory Procedures

Ornidazole-d<sub>5</sub> is intended for use as an internal standard for the quantification of ornidazole (Item No. 26818) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Ornidazole- $d_5$  is supplied as a solid. A stock solution may be made by dissolving the ornidazole- $d_5$  in the solvent of choice, which should be purged with an inert gas. Ornidazole-d<sub>5</sub> is soluble in methanol and DMSO.

# Description

Ornidazole is an orally bioavailable 5-nitroimidazole derivative with antibacterial and antiprotozoal activities.<sup>1,2</sup> Ornidazole inhibits the growth of clinical isolates of B. fragilis (MICs = 0.5-5  $\mu$ M) and various anaerobic bacteria when used at concentrations ranging from less than 0.1 to 3.2 µg/ml.<sup>2,3</sup> It also inhibits the growth of Giardia isolates (IC50s = 0.01-0.47 µg/ml).<sup>4</sup> Oral administration of ornidazole reduces T. vaginalis and T. foetus infection in mice and E. histolytica infection in rats with curative dose ( $CD_{50}$ ) values of 37, 3, and 10 mg/kg, respectively.<sup>1</sup> Ornidazole (400 mg/kg per day) induces infertility in male rats within 7 days and inhibits spermatozoa binding to rat oocyte zona pellucida.<sup>5,6</sup>

# References

- 1. Hoffer, M. and Grunberg, E. J. Med. Chem. 17(9), 1019-1020 (1974).
- 2. Jokipii, L. and Jokipii, A.M. Antimicrob. Agents Chemother. 28(4), 561-564 (1985).
- 3. Wüst, J. Antimicrob. Agents Chemother. 11(4), 631-637 (1977).
- 4. Majewska, A.C., Kasprzak, W., De Jonckheere, J.F., et al. Trans. R. Soc. Trop. Med. Hyg. 85(1), 67-69 (1991).
- 5. Oberländer, G., Yeung, C.H., and Cooper, T.G. J. Reprod. Fertil. 100(2), 551-559 (1994).
- 6. Bone, W., Jones, N.G., Kamp, G., et al. J. Reprod. Fertil. 118(1), 127-135 (2000).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

## SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/07/2023

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM